Related Experiment Video
Updated: Sep 7, 2025

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
Published on: October 6, 2022
Associations between HIV viremia during antiretroviral therapy and cardiovascular disease
Olof Elvstam1,2, Gaetano Marrone3, Gunnar Engström4
1Department of Translational Medicine, Lund University, Malmö.
Insights
Higher HIV viremia exposure during antiretroviral therapy (ART) increases cardiovascular disease (CVD) risk. Low-level viremia showed no increased CVD risk compared to viral suppression in HIV patients.
Area of Science:
- Cardiology
- Infectious Diseases
- Epidemiology
Background:
- Antiretroviral therapy (ART) has transformed HIV management, but cardiovascular disease (CVD) remains a significant concern.
- Understanding the impact of HIV viremia on CVD risk in patients on ART is crucial for optimizing treatment strategies.
Purpose of the Study:
- To investigate the association between HIV viremia exposure during ART and the risk of developing cardiovascular disease (CVD).
Main Methods:
- A nationwide observational cohort study using the Swedish InfCareHIV register (1996-2017).
- Participants were categorized by viremia levels (suppression, low-level, high-level) and cumulative viremia exposure.
- Proportional subhazard models were used to analyze CVD risk, accounting for competing risks.
Main Results:
- Higher cumulative HIV viremia exposure was significantly associated with an increased risk of CVD.
- High-level viremia (≥1000 copies/ml) demonstrated a 45% increased CVD risk compared to viral suppression.
- No significant association was found between low-level viremia and CVD risk.
Conclusions:
- Elevated HIV viremia exposure during ART is linked to a higher risk of CVD in patients.
- Low-level viremia does not appear to elevate CVD risk compared to viral suppression.
- Further research is needed to confirm causality due to the observational nature of the study.
Objective:
To investigate the association between HIV viremia exposure during antiretroviral therapy (ART) and cardiovascular disease (CVD) risk.
Design:
Nationwide observational cohort.
Methods:
Participants (age >15 years) from the Swedish nationwide InfCareHIV register initiating ART 1996-2017 were categorized in a time-updated manner into four viremia categories, starting from 12 months after ART initiation: suppression (<50 copies/ml), low-level viremia (50-199 copies/ml and 200-999 copies/ml, respectively), and high-level viremia (≥1000 copies/ml). In addition, cumulative viremia was estimated as the area under the log viral load (VL) curve. Proportional subhazard models adjusted for sex, age, pre-ART CD4 and VL, injection drug use, and country of birth were used to analyze the association between viremia exposure and CVD risk (ischemic heart disease, stroke, and heart failure; data obtained by linkage to national registers), accounting for the competing risk of non-CVD death.
Results:
In all, 337 cases of CVD were observed during 44 937 person-years of follow-up ( n = 6562). Higher viremia exposure was associated with CVD, both when parameterized as cumulative viremia (adjusted subhazard ratio [aSHR] per 1 log 10 copy × year/ml, 1.03; 95% confidence interval [CI], 1.01-1.05) and as viremia category (aSHR for high-level viremia versus suppression, 1.45; 95% CI, 1.03-2.05). We observed no association between CVD and low-level viremia compared with those with suppression.
Conclusions:
Higher exposure to HIV viremia was linked to CVD in ART recipients, whereas no increased risk was detected for people with low-level viremia compared with viral suppression. Causal inference is limited by the observational nature of this study.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
Coronary Artery Disease III: Clinical Manifestations
Myocarditis III: Medical Management
Coronary Artery Disease II: Pathophysiology
Sexually Transmitted Infections

